La proporción de proteína C reactiva a linfocitoE es un marcador confiable en pacientes con infección por COVID-19; el estudio CLEAR COVID

Autor: Muhammed E. Demirkol, Satilmis Bilgin, Gizem Kahveci, Ozge Kurtkulagi, Burcin M. Atak Tel, Tuba T. Duman, Gulali Aktas

Publikováno v: Cirugía y Cirujanos, Vol 90, Iss 5 (2022)

Objetivo: La infección por Covid-19 se caracteriza por elevación de marcadores inflamatorios en el torrente sanguíneo. Se sugiere que un nuevo marcador inflamatorio, la proporción de C-reactive protein (CRP) a linfocitos (CLR), está asociado con

Externí odkaz: https://doaj.org/article/39154599b73b4887a9c5f24505a0e34c

"That Was an Eye Opener for Me": Mixed-Methods Outcomes Educating Texas Community Health Workers on HPV Vaccination Using Project ECHO ^® .

Autor: Foley S; Interventions and Implementation Department, American Cancer Society, 3380 Chastain Meadows Pkwy NW, Suite 20, Kennesaw, GA 30144, USA., Flowers A; Interventions and Implementation Department, American Cancer Society, 3380 Chastain Meadows Pkwy NW, Suite 20, Kennesaw, GA 30144, USA., Hall T; Interventions and Implementation Department, American Cancer Society, 3380 Chastain Meadows Pkwy NW, Suite 20, Kennesaw, GA 30144, USA., Jansen MT; Independent Researcher, Chapel Hill, NC 27514, USA., Burcin M; Interventions and Implementation Department, American Cancer Society, 3380 Chastain Meadows Pkwy NW, Suite 20, Kennesaw, GA 30144, USA.

Publikováno v: Vaccines [Vaccines (Basel)] 2024 Jul 20; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 20.

A flexible, image-based, high-throughput platform encompassing in-depth cell profiling to identify broad-spectrum coronavirus antivirals with limited off-target effects.

Autor: Doijen J; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: JDoijen@its.jnj.com., Heo I; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: IHeo@its.jnj.com., Temmerman K; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: KTemmer2@ITS.JNJ.com., Vermeulen P; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: PVERMEUL@its.jnj.com., Diels A; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: ADIELS@its.jnj.com., Jaensch S; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: SJAENSCH@its.jnj.com., Burcin M; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: MBurcin@ITS.JNJ.com., Van den Broeck N; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: NVanden6@ITS.JNJ.com., Raeymaekers V; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: VRaeymae@ITS.JNJ.com., Peremans J; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: jpereman@ITS.JNJ.com., Konings K; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: KKoning1@ITS.JNJ.com., Clement M; Charles River Laboratories, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: mcleme12@its.jnj.com., Peeters D; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: DPEETER1@its.jnj.com., Van Loock M; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: mvloock@its.jnj.com., Koul A; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: AKOUL@its.jnj.com., Buyck C; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: CBUYCK@its.jnj.com., Van Gool M; Therapeutics Discovery R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: mvgool2@its.jnj.com., Van Damme E; Global Public Health R&D, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium. Electronic address: evandamm@its.jnj.com.

Publikováno v: Antiviral research [Antiviral Res] 2024 Feb; Vol. 222, pp. 105789. Date of Electronic Publication: 2023 Dec 27.

C-reactive protein-to-lymphocyte ratio is a reliable marker in patients with COVID-19 infection: the CLEAR COVID study

Autor: Muhammed E, Demirkol, Satilmis, Bilgin, Gizem, Kahveci, Ozge, Kurtkulagi, Burcin M, Atak Tel, Tuba T, Duman, Gulali, Aktas

Publikováno v: Cirugia y cirujanos. 90(5)

COVID-19 infection is characterized with elevation of inflammatory markers in bloodstream. A novel inflammatory marker, C-reactive protein (CRP)-to-lymphocyte ratio (CLR), is suggested to be associated with inflammation. We aimed to compare the CLR v

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8917d33b571b63c645e761e2d7a15dc0
https://pubmed.ncbi.nlm.nih.gov/36327470

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.